Clinical Trial Update: A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing daily pravastatin, fenofibrate, and the combination Pravafen for treating combined hyperlipidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Hyperlipidemia

Drugs mentioned

• FENOFIBRATE (Fenofibrate)
• Pravafen (pravastatin + fenofibrate)
• Pravastatin (pravastatin)

Snippet

Sponsor: Shionogi | Conditions: Combined Hyperlipidemia | Phase 3 | Status: COMPLETED